CDKN2A and neoplasm: The pooled OR from six studies including 132 pT2-4 patients and 203 pT1 patients suggested that p16INK4A promoter methylation was significantly correlated with tumor size in RCC (OR = 2.43, 95% CI = 1.10-5.35, P = 0.028) (Table 4), indicating that it was higher in pT2-4 than in pT1.